Zhang Ji, Ni Shuang-Shuang, Zhao Wei-Li, Dong Xiao-Chun, Wang Jin-Lin
Department of Radiology, Changzheng Hospital, Second Military Medical University, No. 415, Fengyang Road, Shanghai, 200003, China.
Tumour Biol. 2013 Aug;34(4):2397-401. doi: 10.1007/s13277-013-0789-9. Epub 2013 Apr 18.
The upregulated expression of JMJD6 was observed in various human cancers. However, little was known about JMJD6 expression and its clinicopathological significance in lung adenocarcinoma. The aim of this study was to investigate the expression and significance of JMJD6 in lung adenocarcinoma progression and prognosis. The levels of JMJD6 mRNA and protein in lung adenocarcinoma specimens and corresponding non-tumorous lung tissues were evaluated by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blot. In order to investigate the correlations between JMJD6 and the clinicopathological features of lung adenocarcinoma, the expression of JMJD6 in 154 patients with lung adenocarcinoma was detected by immunohistochemistry. By qRT-PCR and Western blot, the relative expression levels of JMJD6 mRNA and protein were significantly higher in lung adenocarcinoma tissues than in corresponding non-tumorous lung tissues (P < 0.001). Immunohistochemical staining revealed that high JMJD6 expression was closely correlated with tumor size (P = 0.005), pathological grade (P = 0.003), pT status (P = 0.012), pN status (P = 0.003), and pleural invasion (P < 0.001). Moreover, the results of Kaplan-Meier analysis indicated that a high expression level of JMJD6 resulted in a significantly poor prognosis of lung adenocarcinoma patients. Multivariate analysis showed that the status of JMJD6 expression was an independent prognostic factor for lung adenocarcinoma patients. Our results showed that JMJD6 plays a key role in lung adenocarcinoma and therefore may provide an opportunity for developing a novel therapeutic target as well as a prognostic marker in lung adenocarcinoma.
在多种人类癌症中均观察到JMJD6表达上调。然而，关于JMJD6在肺腺癌中的表达及其临床病理意义却知之甚少。本研究旨在探讨JMJD6在肺腺癌进展和预后中的表达及意义。通过定量逆转录聚合酶链反应（qRT-PCR）和蛋白质免疫印迹法评估肺腺癌标本及相应非肿瘤肺组织中JMJD6 mRNA和蛋白的水平。为了研究JMJD6与肺腺癌临床病理特征之间的相关性，采用免疫组织化学法检测了154例肺腺癌患者中JMJD6的表达。通过qRT-PCR和蛋白质免疫印迹法检测发现，肺腺癌组织中JMJD6 mRNA和蛋白的相对表达水平显著高于相应的非肿瘤肺组织（P < 0.001）。免疫组织化学染色显示，JMJD6高表达与肿瘤大小（P = 0.005）、病理分级（P = 0.003）、pT分期（P = 0.012）、pN分期（P = 0.003）及胸膜侵犯（P < 0.001）密切相关。此外，Kaplan-Meier分析结果表明，JMJD6高表达导致肺腺癌患者预后显著较差。多因素分析显示，JMJD6表达状态是肺腺癌患者的独立预后因素。我们的结果表明，JMJD6在肺腺癌中起关键作用，因此可能为开发新的治疗靶点以及肺腺癌的预后标志物提供契机。
